There is emerging evidence to support pump therapy for patients with type 2 diabetes who require insulin and those with high insulin daily doses who are not achieving adequate glycemic control.6,7 In a multicenter, retrospective study of 81 patients with type 2 diabetes commencing tubeless pump therapy, a reduction in HbA1c of 1.2% after 3 months was observed compared to previous treatment with MDI8 (Figure 5). The gene discussed is INS; the disease is type 2 diabetes mellitus.